Cardiovascular Outcomes Trials (CVOT) and Diabetes: The Clinical Landscape

Review clinical trials supporting medication management in diabetes patients to reduce the risk of cardiovascular events.

Target Audience

Hospitalists, Internists, Family Practitioners, Emergency Medicine Physicians, Surgeons, Cardiologists, Endocrinologists, Physician Assistants, Nurses, Nurse Practitioners, Pharmacists and other interested healthcare practitioners.  

Learning Objectives

  • Evaluate the excess risk of cardiovascular disease (CVD) associated with diabetes mellitus compared to nondiabetic patients.
  • Evaluate the evidence that the use of SGLT2 inhibitors and GLP-1 agonists in diabetic patients is associated with the reduction of CVD.
  • Describe the mechanisms of action for the reduction of CVD with SGLT2 inhibitors and GLP-1 agonists and the lack of relationship to reduction in A1C.
Additional information
  • The Journal of Clinical and Applied Research and Education - Diabetes Care
  • Turnbull FM, et al., Diabetologia 2009; 52; 2288
  • Mazzone, T. Intensive Glucose Lowering and Cardiovascular Disease Prevention in Diabetes:Reconciling the Recent Clinical Trial Data. Circulation. 2010;122:2201–2211
  • Scirica BM, et al. NEJM 2013; 369:1317-1326
  • Udell, et al., Lancet Diabetes Endocrinol., published online 16 March 2015
  • Martín-Timón, I., Sevillano-Collantes, C., Segura-Galindo, A., & del Cañizo-Gómez, F. J. (2014). Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World journal of diabetes, 5(4), 444.
  • Abdul-Ghani, M., Del Prato, S., Chilton, R., & DeFronzo, R. A. (2016). SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes care, 39(5), 717-725.
  • Sun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., ... & Zhan, S. (2015). Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clinical therapeutics, 37(1), 225-241.
Course Summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 General certificate of attendance
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
  • 1.00 Florida Board of Pharmacy
Course opens: 
Course expires: 

Theodore Feldman, M.D., FACC, FACP
Medical Director, Center for Healthcare Advancement & Outcomes
Baptist Health South Florida
Medical Director, Prevention and Community Health
Miami Cardiac & Vascular Institute
Head of Cardiology & Clinical Associate Professor of Medicine
FIU Wertheim College of Medicine

Theodore Feldman, M.D., has indicated that he is on the speakers bureau for Novartis, Regeneron, Sanofi, Amgen, Boehringer Ingelheim and Novo Nordisk and is a consultant for Merck.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 General certificate of attendance
  • 1.00 Nurse Practitioners
  • 1.00 Florida Board of Nursing
  • 1.00 Florida Board of Pharmacy
Please login or register for a Baptist Health CME account to take this course.

NOTE: ABIM MOC points will be submitted by the 15th of the month following completion.

Required Hardware/Software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome
Microsoft Edge
Microsoft Edge
Moxilla Firefox
Mozilla Firefox
Internet Explorer

Attention: Internet Explorer Users
This site offers limited support for Internet Explorer 11 (IE11). When using IE11, you will be prompted to download course videos instead of viewing them in the browser. After the course video downloads, the recordings will play.

Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.